Longitudinal analysis of impulse control disorders in Parkinson disease
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective To investigate the longitudinal dose-effect relationship between dopamine replacement therapy and impulse control disorders (ICDs) in Parkinson disease (PD).
Methods We used data from a multicenter longitudinal cohort of consecutive patients with PD with ≤5 years' disease duration at baseline followed up annually up to 5 years. ICDs were evaluated during face-to-face semistructured interviews with movement disorder specialists. Generalized estimating equations and Poisson models with robust variance were used to study the association between several time-dependent definitions of dopamine agonist (DA) use, taking dose and duration of treatment into account, and ICDs at each visit. Other antiparkinsonian drugs were also examined.
Results Among 411 patients (40.6% women, mean age 62.3 years, average follow-up 3.3 years, SD 1.7 years), 356 (86.6%) took a DA at least once since disease onset. In 306 patients without ICDs at baseline, the 5-year cumulative incidence of ICDs was 46.1% (95% confidence interval [CI] 37.4–55.7, DA ever users 51.5% [95% CI 41.8–62.1], DA never users 12.4% [95% CI 4.8–30.0]). ICD prevalence increased from 19.7% at baseline to 32.8% after 5 years. ICDs were associated with ever DA use (prevalence ratio 4.23, 95% CI 1.78–10.09). Lifetime average daily dose and duration of treatment were independently associated with ICDs with significant dose-effect relationships. Similar analyses for levodopa were not in favor of a strong association. ICDs progressively resolved after DA discontinuation.
Conclusion In this longitudinal study of patients with PD characterized by a high prevalence of DA treatment, the 5-year cumulative incidence of ICDs was ≈46%. ICDs were strongly associated with DA use with a dose-effect relationship; both increasing duration and dose were associated with ICDs. ICDs progressively resolved after DA discontinuation.
ClinicalTrials.gov identifier: NCT01564992.
Glossary
- CI=
- confidence interval;
- DA=
- dopamine agonist;
- DBS=
- deep brain stimulation;
- DIGPD=
- Drug Interaction With Genes in Parkinson's Disease;
- ER=
- extended-release;
- FU=
- follow-up;
- GEE=
- generalized estimating equation;
- ICARUS=
- Impulse Control Disorders and the Association of Neuropsychiatric Symptoms, Cognition and Quality of Life in Parkinson Disease;
- ICD=
- impulse control disorder;
- LD=
- levodopa;
- MDS-UPDRS=
- Movement Disorder Society Unified Parkinson's Disease Rating Scale;
- PD=
- Parkinson disease;
- PR=
- prevalence ratio;
- QIC=
- quasi-information criterion
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Coinvestigators are listed at links.lww.com/WNL/A577.
Editorial, page 107
Podcast: NPub.org/9mi9i9
- Received October 17, 2017.
- Accepted in final form April 11, 2018.
- © 2018 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Association of Neurofilament Light With the Development and Severity of Parkinson Disease
Dr. Rodolfo Savica and Dr. Parichita Choudhury
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Clinical and Ethical Challenges
Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson diseaseHoward D. Weiss, Laura Marsh et al.Neurology: Clinical Practice, December 10, 2012 -
Brief Communications
Clinical features associated with impulse control disorders in Parkinson diseaseGregory Pontone, James R. Williams, Susan Spear Bassett et al.Neurology, October 09, 2006 -
Article
Naltrexone for impulse control disorders in Parkinson diseaseA placebo-controlled studyKimberly Papay, Sharon X. Xie, Matthew Stern et al.Neurology, July 18, 2014 -
Article
Co-occurrence of apathy and impulse control disorders in Parkinson diseaseBonnie M. Scott, Robert S. Eisinger, Matthew R. Burns et al.Neurology, October 01, 2020